BTIG Research Forecasts Strong Price Appreciation for Liquidia (NASDAQ:LQDA) Stock

Liquidia (NASDAQ:LQDA) had its target price lifted by investment analysts at BTIG Research from $49.00 to $50.00 in a report released on Thursday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. BTIG Research’s price target points to a potential upside of 38.77% from the stock’s previous close.

Other equities analysts have also issued research reports about the stock. Wall Street Zen lowered shares of Liquidia from a “buy” rating to a “hold” rating in a research note on Sunday, January 18th. Needham & Company LLC increased their target price on Liquidia from $52.00 to $54.00 and gave the company a “buy” rating in a report on Thursday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Liquidia in a research report on Thursday, January 22nd. Raymond James Financial reiterated a “strong-buy” rating on shares of Liquidia in a report on Thursday. Finally, Zacks Research downgraded Liquidia from a “strong-buy” rating to a “hold” rating in a research note on Friday, February 27th. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $42.00.

Liquidia Trading Up 4.4%

Shares of LQDA opened at $36.03 on Thursday. The company has a current ratio of 2.20, a quick ratio of 1.96 and a debt-to-equity ratio of 6.19. Liquidia has a 1-year low of $11.26 and a 1-year high of $46.67. The stock has a market capitalization of $3.13 billion, a P/E ratio of -43.41, a P/E/G ratio of 0.60 and a beta of 0.52. The business’s 50-day moving average price is $37.10 and its 200 day moving average price is $30.89.

Liquidia (NASDAQ:LQDA) last announced its earnings results on Thursday, March 5th. The company reported $0.15 EPS for the quarter, missing the consensus estimate of $0.33 by ($0.18). Liquidia had a negative return on equity of 237.79% and a negative net margin of 43.53%.The firm had revenue of $92.02 million during the quarter. The firm’s revenue was up 3072.4% compared to the same quarter last year. Analysts expect that Liquidia will post -1.51 earnings per share for the current year.

Insider Buying and Selling

In related news, insider Jason Adair sold 688 shares of Liquidia stock in a transaction on Monday, January 26th. The shares were sold at an average price of $41.65, for a total value of $28,655.20. Following the completion of the sale, the insider owned 211,169 shares of the company’s stock, valued at approximately $8,795,188.85. The trade was a 0.32% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CAO Dana Boyle sold 1,580 shares of the company’s stock in a transaction on Monday, January 26th. The stock was sold at an average price of $41.65, for a total transaction of $65,807.00. Following the completion of the sale, the chief accounting officer owned 178,848 shares of the company’s stock, valued at $7,449,019.20. This represents a 0.88% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 212,534 shares of company stock valued at $7,964,719. 26.50% of the stock is owned by company insiders.

Hedge Funds Weigh In On Liquidia

Several hedge funds have recently bought and sold shares of LQDA. Farallon Capital Management LLC lifted its position in shares of Liquidia by 102.1% in the third quarter. Farallon Capital Management LLC now owns 8,565,638 shares of the company’s stock worth $194,783,000 after buying an additional 4,326,876 shares during the last quarter. TCG Crossover Management LLC acquired a new stake in shares of Liquidia in the third quarter worth about $38,887,000. Caprock Group LLC bought a new stake in shares of Liquidia during the 3rd quarter worth about $37,114,000. Tyro Capital Management LLC bought a new stake in shares of Liquidia during the 2nd quarter worth about $15,473,000. Finally, MPM Bioimpact LLC increased its holdings in shares of Liquidia by 600.4% during the 4th quarter. MPM Bioimpact LLC now owns 1,400,869 shares of the company’s stock valued at $48,316,000 after acquiring an additional 1,200,869 shares during the last quarter. 64.54% of the stock is owned by institutional investors and hedge funds.

More Liquidia News

Here are the key news stories impacting Liquidia this week:

• Positive Sentiment: Commercial momentum and profitability — Liquidia reported YUTREPIA net product sales of $90.1M in Q4 and $148.3M for 2025, achieved a second consecutive profitable quarter (Q4 net income $14.6M) and positive adjusted EBITDA, signaling rapid launch adoption and improving unit economics. GlobeNewswire Release
• Positive Sentiment: Balance sheet strength — the company ended 2025 with ~$190.7M in cash, improving liquidity and backing management’s plan to fund commercial expansion and clinical programs from operations. Quiver Quant Summary
• Positive Sentiment: Analyst upgrades and higher price targets — several firms raised ratings/targets after the quarter (HC Wainwright to $55, Needham to $54, BTIG to $50, Wells Fargo to $44), which supports further upside and likely contributed to intraday buying. Benzinga Analyst Roundup
• Neutral Sentiment: Mixed EPS headlines — Liquidia reported GAAP EPS of $0.15 for Q4. That missed some sell‑side consensus figures (~$0.33) but beat other estimates (Zacks cited $0.08), creating mixed investor interpretation of the results. Zacks Coverage
• Neutral Sentiment: Earnings materials and management commentary available — the slide deck and transcript provide color on commercial adoption, prescriber metrics and plans to fund L606 and other programs; useful for assessing sustainability of the launch. Earnings Presentation (Seeking Alpha)
• Negative Sentiment: Initial market reaction to the EPS headline — shares gapped down on the earnings headline before rebounding, showing sensitivity to EPS versus revenue/profitability nuance. That initial gap indicates headline risk if future quarters miss expectations. DefenseWorld: Gap Down
• Negative Sentiment: Insider and institutional sales — recent filings and summaries show notable insider sell activity and some large institutional reductions, which can weigh on sentiment if sustained. Fool: SEC Filing

About Liquidia

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).